Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel Plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2-Positive Breast Cancer

NCT01008150 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT01008150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01008150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel Plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2-Positive Breast Cancer
Lead sponsor
NSABP Foundation Inc
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
November 25, 2016
Enrollment
141 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer